Protocol Single compound
NAD+
Nicotinamide adenine dinucleotide
Redox coenzyme central to cellular metabolism and sirtuin/PARP activity in in vitro research.
Compare side by side →Laboratory reference · in vitro research data
- Research vial sizes
- 500 mg · 1000 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 500 mg | 1 mL | 500 | 50 |
| 500 mg | 2 mL | 250 | 25 |
| 500 mg | 3 mL | 166.67 | 16.667 |
| 1000 mg | 1 mL | 1,000 | 100 |
| 1000 mg | 2 mL | 500 | 50 |
| 1000 mg | 3 mL | 333.33 | 33.333 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
NAD+ is a coenzyme central to energy metabolism and a substrate for sirtuins and PARP enzymes. Most human trials raise NAD+ indirectly with precursors such as nicotinamide riboside (NR); trials of injected NAD+ itself are scarce.
02
Observed research endpoints
- NADPARK (30 people with early Parkinson's, 30 days): oral NR raised brain NAD levels, changed cerebral metabolism, lowered inflammatory cytokines and was associated with mild clinical improvement.
- Pilot RCT in 20 older adults with mild cognitive impairment (10 weeks): blood NAD+ rose 2.6-fold with NR; cognition scores stayed stable.
03
Regulatory & safety context
- Precursors such as NR are sold as dietary supplements; injectable NAD+ is not an FDA-approved drug.
- Both trials reported NR as well tolerated, with no between-group difference in adverse events in the cognitive-impairment trial. These findings are for NR, not injected NAD+.
04
Citations
- Brakedal B, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396–407.2022-03Phase 1 randomized controlled trialRead paper ↗
- Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46(1):665–682.2024-02Pilot randomized controlled trialRead paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA